Evidence-based Clinical Care: Pulmonary Embolism Clinical Pathway

This course provides practitioners with evidence-based practices related to the risk stratification of pulmonary embolism. This includes practices that promote early suspicion, appropriate diagnostic work-up and consensus treatment algorithms specific to the levels of risk, as well as the recognition of the added value of implementing a Pulmonary Embolism (PERT) Team in the process.

Note to Physicians: Be sure to bookmark this course to access all protocols, pathways, policies and procedures at your convenience via your CME Portal account. All power plans are available in Cerner. All EBCC deliverables will be available on the EBCC website.

Original Release Date: September 2018
Review Date: February 2022, September 2023, February 2024

Target Audience

Cardiothoracic Surgeons, Cardiologists, Critical Care Physicians, Pulmonologists, Emergency Department Physicians, Interventional and Diagnostic Radiologists, Vascular Medicine Specialists, Advanced Practice Providers, Nurses, Nurse Practitioners, Echocardiology Technicians and Hospitalists.

Learning Objectives

  • Explain the necessity of system standardization of treatment options for the pulmonary embolism (PE) patient based on current evidence-based practices.
  • Distinguish severity levels of PE, including massive, sub-massive and low-risk PE, the corresponding clinical pathways and associated power plans, based on evidence-based practices in the acute care setting.
  • Stratify PE patients based on pulmonary thromboembolism (PTE) risk assessment. 
  • Identify a PE utilizing standardized echocardiogram and imaging criteria and implement appropriate treatment. 
  • Monitor quality measures associated with the treatment of PE patients.
  • Recognize the role of the Pulmonary Embolism Response Team (PERT) and Rapid Response Team (RRT) in the diagnosis and treatment of PE.
Additional information
Bibliography: 
  • Stavros V. Konstantinides, MD, Stefano Barco, MD, Mareike Lankeit, MD, Guy Meyer, MD (2016) Management of Pulmonary Embolism. JACC, Vol. 67, No. 8, March 1, 2016: 976-990.
  • Geoffrey Barnes, Jay Giri, D. Mark Courtney, Soophia Naydenov, Todd Wood, Rachel Rosovsky, Kenneth Rosenfield & Christopher Kabrhel (2017) Nuts and bolts of running a pulmonary embolism response team: results from an organizational survey of the National PERT™ Consortium members, Hospital Practice, 45:3, 76-80, DOI: 10.1080/21548331.2017.1309954.
  • Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Single Volume 10th Edition.

 

Course Summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 General certificate of attendance
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
Course opens: 
03/01/2024
Course expires: 
02/28/2025

Javier Perez-Fernandez, M.D.
Pulmonologist 
Director of Pulmonary Services at West Kendall Baptist Hospital
Director of Critical Care Services at Baptist Hospital
Associate Clinical Professor at Florida International University
Miami, Florida

Javier Perez-Fernandez, M.D., faculty for this educational activity, is on the speakers' bureau with Boehringer Ingelheim, Sunovion and Astra-Zeneca and has indicated that the presentation or discussion will not include off-label or unapproved product usage. 

James Benenati, M.D.,  conference director for this educational activity, has indicated that he is a stockholder with Penumbra and a consultant with Bard Medical and Penumbra.

Ian del Conde Pozzi, M.D., conference director for this educational activity, has no relevant financial relationship with ineligible companies* to disclose.

Ripal Gandhi, M.D., has indicated that he is a consultant with Bard, BTG, Sirtex, Medtronic and Boston SCI. 

Adam Geronemus, M.D., has indicated that he is on the speakers' bureau with Gore, Bard and Merit.

F. Javier Jimenez-Carcamo, M.D., has indicated that he is on the speakers' bureau with Bayer, Actelion and United Therapeutics and on the advisory board with Actelion and United Therapeutics.

All of the relevant financial relationships listed for these individuals have been mitigated.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.

*Ineligible companies -- Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 General certificate of attendance
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
Please login or register for a Baptist Health CME account to take this course.

Required Hardware/Software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome
Microsoft Edge
Microsoft Edge
Safari
Safari
Moxilla Firefox
Mozilla Firefox
Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.